Abstract
Abstract
Background
Published in 2019, a new addendum to the ICH E9 guideline presents the estimand framework as a systematic approach to ensure alignment among clinical trial objectives, trial execution/conduct, statistical analyses, and interpretation of results. The use of the estimand framework for describing clinical trial objectives has yet to be extensively considered in the context of patient-reported outcomes (PROs). We discuss the application of the estimand framework to PRO objectives when designing clinical trials in the future, with a focus on PRO outcomes in oncology trial settings as our example.
Main
We describe the components of an estimand and take a naïve PRO trial objective to illustrate how to apply attributes described in the estimand framework to inform construction of a detailed clinical trial objective and its related estimand. We discuss identifying potential post-randomization events that alter the interpretation of the endpoint or render its observation impossible (also defined as intercurrent events) in the context of PRO endpoints, and the implications of how to handle intercurrent events in the construction of the PRO objective. Using a simple objective statement, “What is the effect of treatment X on patient’s quality of life?”, we build up an example estimand statement and also use a previously published phase III oncology clinical trial to illustrate how an estimand for a PRO objective could have been written to align to the estimate framework.
Conclusion
The use of the estimand framework, as described in the new ICH E9 (R1) addendum guideline will become a key common framework for developing clinical trial objectives for evaluating effects of treatment. In the context of considering PROs, the framework provides an opportunity to more precisely specify and build the rationale for patient-focused objectives. This will help to ensure that clinical trials used for registration are designed and analysed appropriately, enabling all stakeholders to accurately interpret conclusions about the treatment effects for patient-focused outcomes.
Publisher
Springer Science and Business Media LLC
Subject
Health Information Management,Health Informatics
Reference19 articles.
1. Institute of Medicine. Crossing the quality chasm: a new health system for the 21st Century (http://www.nationalacademies.org/hmd/~/media/Files/Report%20Files/2001/Crossing-the-Quality-Chasm/Quality%20Chasm%202001%20%20report%20brief.pdf). 2001.
2. International Council for Harmonisation. Addendum on estimands and sensitivity analysis in clinical trials to the guideline om statistical principles for clinical trials E9(R) (https://database.ich.org/sites/default/files/E9-R1_Step4_Guideline_2019_1203.pdf). 2019.
3. Huang, X., Lin, J., & Demner-Fushman, D. (2006). Evaluation of PICO as a knowledge representation for clinical questions. AMIA Annual Symposium Proceedings, 2006, 359–363.
4. Bottomley, A., Pe, M., Sloan, J., et al. (2016). Analysing data from patient-reported outcome and quality of life endpoints for cancer clinical trials: a start in setting international standards. The Lancet Oncology, 17(11), e510–e514.
5. Coens, C., Pe, M., Dueck, A. C., et al. (2020). International standards for the analysis of quality of life and patient reported outcomes endpoints in cancer randomised controlled trials; recommendations based on critical reviews of the literature and international multi-expert, multi-stakeholder collaborative process. The Lancet Oncology, 21, e83–e96.
Cited by
41 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献